WA-AMAZON.COM
3.11.2022 12:09:44 CET | Business Wire | Press release
Amazon and the U.S. Agency for International Development (USAID) are launching a public-private partnership to address the gender inequities that exist for women in the climate finance ecosystem and support female entrepreneurs with the resources they need to accelerate climate change innovations.
Amazon will commit a total of $53 million to help accelerate women’s climate solutions, including $3 million toward the USAID partnership and $50 million for Amazon to invest directly in climate tech companies run by women.
Amazon will serve as a founding partner of USAID’s Climate Gender Equity Fund, a new climate finance facility designed to remove systemic market barriers that prevent women and girls from accessing climate finance. USAID will also match Amazon’s $3 million investment to help launch the fund.
The Climate Gender Equity Fund will have a global focus and provide grants for businesses, NGOs, accelerators, incubators, and grassroots organizations working on women-led climate solutions. It also will fund efforts to help women access the networks and technical skills they need to accelerate the development of their climate change technologies.
As a co-founder of The Climate Pledge, a commitment to reach net-zero carbon emissions by 2040, Amazon will work with Pledge signatories and other companies to encourage their additional support and corporate investment in this new fund. The partnership will help advance mutual goals around women’s climate leadership and gender equity, including Amazon’s sustainability goals, the work of The Climate Pledge, and the Biden administration’s National Strategy on Gender Equity and Equality.
Additionally, Amazon is allocating $50 million from its Climate Pledge Fund to invest in women-founded and women-led climate tech companies, as well as incubators and accelerators that prioritize women-led entities. The Climate Pledge Fund–Amazon’s venture capital program that invests in companies pioneering decarbonizing technologies and solutions–will collaborate with USAID and the Climate Gender Equity Fund to source new investment opportunities and broaden its pipeline of female applicants.
“As an important step in solving climate change, we must address the gender inequalities that persist in climate finance, and ensure female entrepreneurs have an equal seat at the table and access to the funding, networks, and technical support they need to scale climate solutions,” said Kara Hurst, vice president of Worldwide Sustainability at Amazon. “We’re proud to collaborate with USAID and the Biden administration to help scale women-led climate solutions globally. This is just one part of our broader Climate Pledge goal to reach net-zero carbon by 2040, and we encourage other companies to join us in this effort.”
Female-founded companies typically receive a fraction of global venture capital, and that percentage fell during the pandemic. However, research shows that female entrepreneurs are more likely than their male counterparts to innovate to address social needs. Women-led companies also generate more revenue per dollar invested and produce greater ROI for investors.
Amazon has recently taken several additional steps to advance gender equality across its value chain, including:
- Committing to the United Nations Women's Empowerment Principles (WEPs), which offer businesses guidance on ways to promote gender equity and empower women in the workplace, marketplace, and community.
- Granting $1 million to the Resilience Fund for Women in Global Value Chains, which is investing in organizations supporting women in global value chains, including manufacturing, apparel, and agriculture, with a focus on gender-based violence and reproductive health.
- Partnering with BSR’s HERproject to combat gender-based discrimination in China, Bangladesh, Vietnam, and India by engaging suppliers, factory workers, and management. These efforts have reached nearly 10,000 women.
- Investing in the Elevate Future Fund, which increases funding to women and other underrepresented founders working on climate tech solutions, as well as firms creating economic opportunity for distressed and disadvantaged communities. This investment is part of the new Amazon Catalytic Capital initiative to provide underrepresented entrepreneurs with access to capital.
- Collaborating with Greentown Labs, North America’s largest climate tech incubator, to source and engage with new startups. The Climate Pledge Fund participates in pitch events, including “Access to Success,” a community event for diverse founders. Amazon also serves on Greentown Labs’ Industry Leadership Council.
- Working with Elemental Excelerator, a climate tech startup accelerator that is a leader in promoting diversity, equity, and inclusion principles in climate tech. Elemental Excelerator recently launched an Equity & Access program that helps startup founders build equity into their organizations’ teams and activities.
Learn more about Amazon’s sustainability efforts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005180/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
